Literature DB >> 8520793

Effect of acute and chronic inhaled furosemide on bronchial hyperresponsiveness in mild asthma.

D H Yates1, B J O'Connor, G Yilmaz, S Aikman, M Worsdell, P J Barnes, K F Chung.   

Abstract

We determined whether chronic administration of furosemide aerosol would be beneficial for the treatment of asthma. First, we showed that furosemide aerosol delivered from a metered-dose inhaler (10 and 20 mg) significantly protected against sodium metabisulfite (MBS) challenge by 0.6 and 1.3 doubling dilutions respectively in 12 volunteers with mild asthma. In a double-blind cross-over study, we examined the effect of furosemide aerosol from a twice more efficient metered-dose inhaler (10 mg four times per day) inhaled over 4 wk versus placebo in 12 other asthmatic subjects. There was no significant effect of furosemide on bronchial responsiveness to methacholine or MBS. Treatment with furosemide over 1 mo did not improve bronchial hyperresponsiveness in subjects with mild asthma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8520793     DOI: 10.1164/ajrccm.152.6.8520793

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  2 in total

1.  The effect of levocabastine and furosemide pretreatment on hyperreactive response after nasal provocation with hypotonic aerosol in subjects with allergic rhinitis.

Authors:  Srdjan Ante Anzic; Davor Dzepina; Livije Kalogjera
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-07-06       Impact factor: 2.503

2.  The efficacy of nebulized furosemide and salbutamol compared with salbutamol alone in reactive airway disease: a double blind randomized, clinical trial.

Authors:  Kambiz Masoumi; Arash Forouzan; Maryam Haddadzadeh Shoushtari; Samaneh Porozan; Maryam Feli; Mehdi Fallah Bagher Sheidaee; Ali Asgari Darian
Journal:  Emerg Med Int       Date:  2014-04-27       Impact factor: 1.112

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.